Research Article

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

Table 3

Proportion of patients within Hb target ranges (efficacy population).

Hb rangeVisit window
7–9a7–127–15

11-12 g/dL20.7% (40/193)2.9% (4/137)0.0% (0/153)
11–13 g/dL40.4% (78/193)21.2% (29/137)15.0% (23/153)
10–12 g/dL42.0% (81/193)24.1% (33/137)14.4% (22/153)
10–13 g/dL64.8% (125/193)52.6% (72/137)43.1% (66/153)

Prespecified evaluation period.